Herpes Zoster VaccineA Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Sponsor:

Beijing Luzhu Biotechnology Co., Ltd.

Code:

NCT05750017

Conditions

Herpes Zoster

Vaccine-Preventable Diseases

Eligibility Criteria

Sex: All

Age: 50 - 70

Healthy Volunteers: Accepted

Interventions

Low Dose Recombinant Herpes Zoster Vaccine (LZ901)

High Dose Recombinant Herpes Zoster Vaccine (LZ901)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-26. This information was provided to ClinicalTrials.gov by Beijing Luzhu Biotechnology Co., Ltd. on 2023-03-27.